A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer

by Muhammad Hamid, MD, Lance K. Heilbrun, PhD, Jordan Maier, MD, Kiran Devisetty, MD, Irene Connolly, MD, Isaac Kaufman, MD, Kimberlee Dobson, BSME, CCRP, Mackenzie K. Herroon, MA, Daryn Smith, MSc, Sandra Sampson, RN, OCN, Izabela Podgorski, PhD, Elisabeth I. Heath, MD
Published 2021-07-01